Paul A. Brooke – Chairman of the Board of Directors
Mr. Brooke has served as a member of our Board of Directors since June 2018 and as Chairman of the Board of Directors since July 2018. He was a founder and managing partner of venBio, LLC, a pharmaceutical investment company, from which he retired at the end of 2016. Mr. Brooke was Chairman of the Board of Directors of Alsius Corporation, a medical device company, from June 2007 through its sale in May 2009, and was the Chairman and Chief Executive Officer of a predecessor company from April 2005 to June 2007. Mr. Brooke has been the Managing Member of PMSV Holdings, LLC, a private investment firm, since 1993. He also served as a Senior Advisor to Morgan Stanley & Co. Incorporated from April 2000 to December 2009, and was a Venture Partner at MPM Capital, a venture capital firm specializing in the healthcare industry, from 1997 through 2006. From April 1999 through May 2000, Mr. Brooke served as a Managing Director at Tiger Management LLC. He was a Managing Director and the Global Head of Healthcare Research and Strategy at Morgan Stanley & Co. from 1983 to April 1999. Mr. Brooke is also a director of several privately held companies. Mr. Brooke was selected to serve on our Board of Directors because he has leadership experience and insight into the operations, challenges and complex issues facing healthcare companies gained from his experience as head of healthcare research at a major investment bank and as an investor.

Lindsay A. Rosenwald, M.D. – Director
Dr. Rosenwald has almost 25 years of experience as a biotechnology entrepreneur, including the founding and recapitalization of numerous public and private biotechnology and life sciences companies. In addition to serving as a director of Caelum, Dr. Rosenwald is Chairman, President and CEO of Fortress Biotech, Caelum’s parent company. Dr. Rosenwald is also a Co-Portfolio Manager and Partner at Opus Point Partners Management, LLC, a life-science focused asset management firm. Before moving into his current positions, Dr. Rosenwald served as Chairman of Paramount BioCapital, Inc. Dr. Rosenwald received an M.D. from Temple University School of Medicine and a B.S. in finance from Pennsylvania State University.

Michael Spector – President and Chief Executive Officer and Director
Mr. Spector was named President and Chief Executive Officer in January 2017 and has served on our board of directors since March 2017. He joined Caelum from Fortress Biotech, where he leveraged more than 25 years of biotechnology experience to identify emerging and innovative technologies to launch as new biotech and specialty pharmaceutical companies. Prior to Fortress, Mr. Spector served as Senior Vice President, Global Commercial Operations at Iroko Pharmaceuticals. Earlier in his career, he spent 15 years at GlaxoSmithKline in multiple senior management positions, including Vice President and General Manager of GlaxoSmithKline South Africa, where he led the overall business strategy and was elected to run the South African Pharmaceutical Manufacturers Association. Mr. Spector is also a founding member of Windhoek Healthcare, where he launched two specialty pharmaceutical companies: Laurel Pharmaceuticals and North Creek Pharmaceuticals. Mr. Spector holds an M.B.A. from Rider University in Lawrenceville, N.J., where he serves on the Business and Scientific Advisory Boards, and a B.S. in biology from the University of Pittsburgh. He also serves on the Board of Directors of Jacaranda Health, a nonprofit organization that seeks to transform maternal and neonatal healthcare in East Africa.

Martin Goldman, M.D. – Director
Dr. Goldman began serving on our Board in June 2017.  He is a chaired professor, Vice Chair for Education, Program Director of the Academic Program Training and Associate Director of Cardiology at a major academic medical center in New York City . He also has a large referral practice in clinical cardiology.  He holds a certifications in internal medicine and cardiovascular disease from the American Board of Internal Medicine.  Dr. Goldman received his M.D. at Albert Einstein College of Medicine and completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital at Harvard Medical School . He did his cardiology fellowship and advanced cardiac imaging at Mount Sinai, NYC. He has published over 200 scientific articles.

William Natbony – Director
Mr. Natbony has served on our Board since June 2017.  He is the CEO and Executive Chairman of the Zander Ridge Group, a private family office, and previously was the CEO and Executive Chairman of Tigris Group Inc., a diversified multi-billion dollar family office. Prior to joining Tigris, Mr. Natbony was a senior partner at the international law firm of Katten Muchin Rosenman LLP and was listed in Leading Lawyers in America, New York Super Lawyers and Best Lawyers in America. Mr. Natbony currently holds directorships at Gabriel Resources Ltd., a resources company listed on the Toronto Stock Exchange, Electrum Ltd., a privately-held gold exploration company, Sunshine Silver Mining & Refining Corporation, a privately-held silver exploration and development company, and Panthera Corp. and the Orianne Society, charities that support wildlife conservation. Mr. Natbony holds a J.D. and an LL.M. (in Taxation) from New York University and has been a member of the New York Bar since 1976.

Harlan Weisman, M.D. – Director
Dr. Weisman joined our Board of Directors in December 2018.  He has 30 years experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Dr. Weisman is also on the Board of Directors of ControlRad, Inc., 3DBio Therapeutics and TFF Pharmaceuticals.  He is a Senior Advisor to CRG, a healthcare investment firm and a Venture Advisor to the Israel Biotech Fund. He is on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences, Memorial Sloan Kettering Cancer Center and BioMotiv, a medical product accelerator company.

Previously, Dr. Weisman was Chairman and CEO of Coronado Biosciences, Inc., a biopharmaceutical company that was developing novel immunotherapies for autoimmune diseases and cancer. Prior to Coronado, he was a senior executive at Johnson & Johnson for over 20 years. Dr. Weisman was the Chief Science and Technology Officer of the J&J Medical Devices and Diagnostics Group from 2006-2012. He served on the Board of Directors of J&J Development Corporation (JJDC) and as Chairman of the J&J Worldwide R&D Council. Preceding these roles, he was Company Group Chairman, J&J Pharmaceutical Research & Development, and before this he was President of Centocor R&D. Prior to joining industry, Dr. Weisman was Assistant Professor of Medicine at Johns Hopkins University School of Medicine and Consultant Cardiologist at Johns Hopkins Hospital. He has a B.A. from the University of Maryland and M.D. from the University of Maryland School of Medicine. Dr. Weisman completed an Internal Medicine residency at Mount Sinai Hospital in New York and a fellowship in cardiovascular disease at Johns Hopkins Medical Institutions. Dr. Weisman has authored more than 100 articles and book chapters about cardiovascular disease, medical product development, healthcare policy and organizational development.

Martine Zimmerman, Pharm.D. – Director
Dr. Zimmerman has served on our Board since March 2019.  Dr. Zimmerman is the Senior Vice President and Head of Global Regulatory Affairs at Alexion Pharmaceuticals. Based in Zurich, she has over 20 years of combined R&D and global regulatory strategy experience. She joined Alexion in 2009 and since then has been dedicated to the registration of Orphan Medical products as well as shaping a favorable regulatory environment for orphans. Throughout her career, Dr. Zimmerman has been directly involved in multiple regulatory approvals across the globe and most recently Strensiq approval in 2015 in Japan, Europe and the U.S. Dr. Zimmerman received her Pharm.D. from University Louis Pasteur in Strasbourg (France).